Through its wholly owned subsidiaries, Serac Life Sciences is developing two late stage and complimentary assets to target major unmet medical and societal needs and have significant commercial potential.

These game-changing molecular imaging technologies are aimed at improving quality of care, increasing access to care whilst reducing healthcare system costs.

Our highly experienced team have between them led the development, launch and successful commercialisation of radiopharmaceuticals, x-ray and MR contrast media as well as nuclear medicine, ultrasound, MR and CT scanners for the industry’s leading global players.

If you would like to learn more please contact:

David Hail, CEO